What makes mAbs highly attractive is the ability of IgG1 mAbs to induce antibody-dependent cell-mediated cytotoxicity (ADCC) through Fc receptor-bearing immune cells, increasing tumor immunogenicity and providing a rationale to combine anti-EGFR mAbs with immunotherapies. This evidence concerns the gene EGFR and neoplasm.